Suppr超能文献

补钙与非甾体抗炎药的相互作用及结直肠腺瘤风险

Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.

作者信息

Grau Maria V, Baron John A, Barry Elizabeth L, Sandler Robert S, Haile Robert W, Mandel Jack S, Cole Bernard F

机构信息

Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, New Hamsphire, USA.

出版信息

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2353-8. doi: 10.1158/1055-9965.EPI-05-0003.

Abstract

BACKGROUND

Calcium and aspirin have both been found to be chemopreventive against colorectal neoplasia. However, the joint effect of the two agents has not been well investigated.

METHODS

To explore the separate and joint effects of calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data from two large randomized clinical trials among patients with a recent history of colorectal adenomas. In the Calcium Polyp Prevention Study, 930 eligible subjects were randomized to receive placebo or 1,200 mg of elemental calcium daily for 4 years. In the Aspirin/Folate Polyp Prevention Study, 1,121 eligible subjects were assigned to take placebo, 81 mg of aspirin, or 325 mg of aspirin daily for 3 years. In each study, subjects completed a validated food frequency questionnaire at enrollment and were asked periodically about medications and supplements used. Recurrent adenomas and advanced adenomas were the end points considered. We used generalized linear models to assess the separate and combined effects of aspirin (or NSAIDs) and calcium supplementation (or dietary calcium) and the interactions between these exposures.

RESULTS

In the Calcium Trial, subjects randomized to calcium who also were frequent users of NSAIDs had a reduction of risk for advanced adenomas of 65% [adjusted risk ratio (RR), 0.35; 95% confidence interval (95% CI), 0.13-0.96], and there was a highly significant statistical interaction between calcium treatment and frequent NSAID use (P(interaction) = 0.01). Similarly, in the Aspirin Trial, 81 mg aspirin and calcium supplement use together conferred a risk reduction of 80% for advanced adenomas (adjusted RR, 0.20; 95% CI, 0.05-0.81); there was a borderline significant statistical interaction between the two treatments (P(interaction) = 0.09). In this trial, we found similar trends when we considered baseline dietary calcium intake instead of calcium supplements. For all adenomas considered together, the interactive patterns were not consistent.

CONCLUSION

Data from two different randomized clinical trials suggest that calcium and NSAIDs may act synergistically to lower the risk of advanced colorectal neoplastic polyps.

摘要

背景

钙和阿司匹林均已被发现对结直肠肿瘤具有化学预防作用。然而,这两种药物的联合效果尚未得到充分研究。

方法

为探究钙与阿司匹林/非甾体抗炎药(NSAID)的单独及联合作用,我们使用了两项针对近期有结直肠腺瘤病史患者的大型随机临床试验数据。在钙息肉预防研究中,930名符合条件的受试者被随机分为两组,一组每日服用安慰剂,另一组每日服用1200毫克元素钙,为期4年。在阿司匹林/叶酸息肉预防研究中,1121名符合条件的受试者被分配为每日服用安慰剂、81毫克阿司匹林或325毫克阿司匹林,为期3年。在每项研究中,受试者在入组时完成一份经过验证的食物频率问卷,并定期询问所使用的药物和补充剂情况。复发性腺瘤和进展性腺瘤为所考虑的终点。我们使用广义线性模型来评估阿司匹林(或NSAID)和钙补充剂(或膳食钙)的单独及联合作用,以及这些暴露之间的相互作用。

结果

在钙试验中,随机分配到钙组且同时频繁使用NSAID的受试者进展性腺瘤风险降低了65%[校正风险比(RR),0.35;95%置信区间(95%CI),0.13 - 0.96],并且钙治疗与频繁使用NSAID之间存在高度显著的统计学交互作用(P(交互作用)= 0.01)。同样,在阿司匹林试验中,81毫克阿司匹林与钙补充剂共同使用使进展性腺瘤风险降低了80%(校正RR,0.20;95%CI,0.05 - 0.81);两种治疗之间存在边缘显著的统计学交互作用(P(交互作用)= 0.09)。在该试验中,当我们考虑基线膳食钙摄入量而非钙补充剂时,发现了类似的趋势。对于所有一起考虑的腺瘤,交互模式并不一致。

结论

来自两项不同随机临床试验的数据表明,钙和NSAID可能协同作用以降低进展性结直肠肿瘤性息肉的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验